Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for PTKFF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for PTKFF and 80,000+ other tickers.
See exactly how PTKFF's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PTKFF and 80,000+ other tickers.
Indonesia-based pharmaceutical powerhouse, PT Kalbe Farma Tbk., along with its affiliated companies, is engaged in the development, manufacturing, and commercialization of a broad spectrum of pharmaceutical products throughout the country. The organization structures its operations across four primary business units: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistic. It offers a diverse range of medications, including generic, branded, and licensed drugs such as Brainact, Cefspan, Mycoral, Cernevit, Cravit, Neuralgin, Broadced, Neurotam, Hemapo, and…
No recent news available.